Compare · DXCM vs IINN
DXCM vs IINN
Side-by-side comparison of DexCom Inc. (DXCM) and Inspira Technologies Oxy B.H.N. Ltd. (IINN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IINN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.06B, about 1681.7x IINN ($16.7M).
- Over the past year, DXCM is down 13.6% and IINN is down 72.8% - DXCM leads by 59.2 points.
- IINN has been more active in the news (15 items in the past 4 weeks vs 5 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- DexCom Inc.
- Inspira Technologies Oxy B.H.N. Ltd.
- Price
- $72.69-1.96%
- $0.38+0.51%
- Market cap
- $28.06B
- $16.7M
- 1M return
- -3.56%
- -34.36%
- 1Y return
- -13.63%
- -72.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 5
- 15
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest DXCM
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Latest IINN
- SEC Form 25-NSE filed by Inspira Technologies Oxy B.H.N. Ltd.
- COO Shabtay Abraham was granted 550,000 units of Ordinary Shares, increasing direct ownership by 41% to 1,882,713 units (SEC Form 4)
- Chief Business Officer Rozanovich Yoav was granted 550,000 units of Ordinary Shares (SEC Form 4)
- Chief Technology Officer Yechezkely Hayon Daniella was granted 550,000 units of Ordinary Shares, increasing direct ownership by 71% to 1,330,000 units (SEC Form 4)
- Chief Financial Officer Tehila Yafit was granted 550,000 units of Ordinary Shares, increasing direct ownership by 63% to 1,420,000 units (SEC Form 4)
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Secures Commercial Order and Begins Production for Leading International Government-Owned Company
- SEC Form EFFECT filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Establishes U.S. Subsidiary to Advance Federal Government Contracting
- SEC Form POS AM filed by Inspira Technologies Oxy B.H.N. Ltd.